MedTrace Logo

Erythropoietin in Hemolytic Uremic Syndrome

NCT03776851 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-01-13

No results posted yet for this study

Summary

This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

Conditions

  • Hemolytic-Uremic Syndrome
  • Anemia

Interventions

DRUG

erythropoietin

erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route

Sponsors & Collaborators

  • Hospital General de Niños Pedro de Elizalde

    lead OTHER

Principal Investigators

  • Alejandro Balestracci, MD, PhD · Hospital General de Niños Pedro de Elizalde

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • Argentina

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03776851 on ClinicalTrials.gov